# US 2014/0271465 A1 · Matrix metalloprotease (mmp) targeted agents for imaging and therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0271465 A1
- Document ID: US20140271465A1
- Status: Published application
- Kind: A1
- Application number: 14/208,350
- Filed: 2014-03-13
- Published: 2014-09-18
- Earliest claimed: 2013-03-15
- Assignees: Mallinckrodt Inc.
- Applicants: Mallinckrodt LLC
- Inventors: John N. Freskos; Mary Dyszlewski; Lori Chinen; Hector Knight; Michelle Schmidt
- Web page: https://patentgrep.com/patent/US20140271465A1

## CPC

- A61K 51/0482: {chelates from cyclic ligands, e.g. DOTA}
- A61K 31/4523: containing further heterocyclic ring systems
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 51/0455: {having six-membered rings with one nitrogen as the only ring hetero atom}
- A61K 51/0478: {complexes from non-cyclic ligands, e.g. EDTA, MAG3}
- A61K 51/048: {DTPA (diethylenetriamine tetraacetic acid)}
- A61P 35/00: Antineoplastic agents
- C07D 211/66: having a hetero atom as the second substituent in position 4
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention provides compound conjugates of matrix metalloprotease inhibitors and linked metal chelators which are useful for imaging solid tumors and treating and diagnosing certain types of diseases such as cancer.

## Claims

### Claim 1

A compound conjugate comprising a matrix metalloprotease inhibitor (MMPi) portion and a linked metal chelator portion.

### Claim 2 (depends on 1)

The conjugate of claim 1, wherein the MMPi is linked to the metal chelator portion by a bifunctional linker.

### Claim 3 (depends on 2)

The conjugate of claim 2, wherein the bifunctional linker has the following structure
wherein A1 indicates the point of attachment to the MMPi portion; and
A2 indicates the point of attachment to the metal chelator portion.

### Claim 4 (depends on 1)

The conjugate of claim 1, having the following structure:
wherein R1 is selected from the group consisting of O and S;
wherein R2 is selected from the group consisting of pyridyl and phenyl;
wherein when R2 is phenyl, said phenyl at R2 is optionally substituted with 1 to 5 substituents selected from the group consisting of OH, OCH3, OCF3 and CH3; and
wherein R3 is the linked metal chelator portion.

### Claim 5 (depends on 4)

The conjugate of claim 4, wherein R3 is selected from the group consisting of
and
wherein the wavy line indicates the point of attachment to the remainder of the conjugate.

### Claim 6 (depends on 4)

The conjugate of claim 4, having the following structure:
wherein R4 is selected from the group consisting of
and
wherein the wavy line indicates the point of attachment at R4.

### Claim 7 (depends on 4)

The conjugate of claim 4, having a structure selected from the group consisting of

### Claim 8 (depends on 4)

The conjugate of claim 4, having a structure selected from the group consisting of

### Claim 9 (depends on 1)

The conjugate of claim 1, and further comprising a radionuclide.

### Claim 10 (depends on 9)

The conjugate of claim 9, wherein said radionuclide is selected from the group consisting of 225Ac, 72As, 211At, 11B, 128Ba, 212Bi, 75Br, 77Br, 14C, 109Cd, 62Cu, 64Cu, 67Cu, 18F, 67Ga, 68Ga, 3H, 123I, 125I, 130I, 131I, 111In, 177Lu, 13N, 15O, 32P, 33P, 212Pb, 103Pd, 186re, 188Re, 47Sc, 153Sm, 89Sr, 99mTc, 88Y and 90Y.

### Claim 11 (depends on 9)

The conjugate of claim 9, wherein said radionuclide is selected from the group consisting of 111In and 99mTc.

### Claim 12 (depends on 1)

The conjugate of claim 1, and further comprising a lanthanide.

### Claim 13 (depends on 1)

The conjugate of claim 1, and further comprising a lipid, a liposome, a micelle, a lipid-coated bubble, or a block copolymer micelle.

### Claim 14 (depends on 13)

The conjugate of claim 13, wherein said lipid is a phospholipid, glycolipid, sphingolipid, or cholesterol.

### Claim 15 (depends on 1)

The conjugate of claim 1, and further comprising a stealth agent.

### Claim 16 (depends on 15)

The conjugate of claim 15, wherein said stealth agent is poly(ethylene glycol).

### Claim 17 (depends on 1)

A pharmaceutical composition comprising a conjugate of claim 1.

### Claim 18

A method of diagnosing the presence of solid tumors in a patient, the method comprising the following steps:
administering a compound conjugate comprising a matrix metalloprotease inhibitor (MMPi) portion and a linked metal chelator portion to a patient;
acquiring a contrast image of the administered conjugate, or fragment thereof, in the patient;
analyzing said contrast image to determine the concentration of MMP enzymes; and;
diagnosing the presence of solid tumors based on said determination of the concentration of MMP enzymes;
wherein a locally high concentration of MMP enzymes indicates a diagnosis of solid tumors.

### Claim 19 (depends on 18)

The method of claim 18, wherein the solid tumors are associated with a disease or condition selected from the group consisting of cancer, carcinoma, sarcoma, leukemia, lymphoma, myeloma, central nervous system cancer, solid tumors, and mixed tumors.

### Claim 20

A method for treating a patient having solid tumors, the method comprising:
administering a compound conjugate comprising a matrix metalloprotease inhibitor (MMPi) portion and a linked metal chelator portion to a patient having solid tumors;
thereby treating a patient having solid tumors.
